https://www.selleckchem.com/products/abt-199.html
The presence of autoimmune events were recorded in patients receiving immunecheckpoint inhibitors. Retrospective study in patients receiving immune checkpoint inhibitors (ICIs) during the period of 2012-2019. A total of 554patients received ICIs of which 123 developed an immune related adverse event. Twenty one (17%) with toxicity were identified as having apre-existing autoimmune disease and 88 required treatment with corticosteroids or hormone replacement. Thirty two (26%) out of 123 had to temporarilydiscontinue ICIsdue to autoimmune